KRAS and colorectal carcinoma: A promising clinical result from a TILs transfer therapy in 2016 showed that infusion of TILs specifically against KRAS G12D in a metastatic CRC patient resulted in tumor regression in all seven metastatic lung lesions for 40 days, followed by one lesion progression after 9 months 49.